Treatment response, survival and safety profile of transarterial chemoembolization using different sizes of drug-eluting beads in hepatocellular carcinoma patients with portal vein tumor thrombus - 28/05/22
Highlights |
• | In HCC patients with PVTT, ORR was similar but DCR was highest in 300–500 μm group. |
• | In HCC patients with PVTT, OS and adverse events were similar among groups. |
• | In HCC patients without PVTT, ORR, DCR and OS were similar among three groups. |
• | In HCC patients without PVTT, fever incidence was highest in 300–500 μm group. |
• | DEB-TACE with 300–500 μm microspheres might be a choice in HCC patients with PVTT. |
Abstract |
Background |
Different sized microspheres may affect the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) in hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT), but related data are lacking. Therefore, the current study aimed to investigate the treatment response, survival and safety of DEB-TACE using different sized microspheres in HCC patients with or without PVTT.
Methods |
Totally 90 HCC patients underwent DEB-TACE treatment were retrospectively enrolled (30 cases with PVTT and 60 cases without PVTT). According to the sizes of microspheres, patients were divided into 100–300 μm, 300–500 μm and 500–700 μm groups, respectively.
Results |
Disease control rate (DCR) was highest in 300–500 μm group (81.3%), followed by 500–700 μm group (50.0%), then the lowest in 100–300 μm group (12.5%) (P = 0.004); while objective response rate (ORR) was similar among three groups (P = 0.177) in patients with PVTT. Furthermore, overall survival (OS) (P = 0.513) and adverse events (all P>0.05) were similar among three groups in patients with PVTT. Besides, in patients without PVTT: ORR (P = 0.694), DCR (P = 0.591), OS (P = 0.816) were of no difference among three groups; but the fever incidence was highest in 300–500 μm group (65.0%), second high in 500–700 μm group (50.0%), then lowest in 100–300 μm group (25.0%) (P = 0.008), except for this, no difference of other adverse events among three groups was found (all P>0.05).
Conclusion |
DEB-TACE using 300–500 μm microspheres (versus 100–300 μm or 500–700 μm microspheres) exhibits best treatment response without additional adverse events, indicating it might be the optimal choice for HCC patients with PVTT.
Il testo completo di questo articolo è disponibile in PDF.Keywords : Drug-eluting beads transarterial chemoembolization, Hepatocellular carcinoma, Portal vein tumor thrombus, Different sizes of microspheres, Prognosis
Abbreviations : PVTT, HCC, TACE, cTACE, DEB-TACE, EMRS, ECOG, BCLC, CNLC, ORR, DCR, OS, SD, ANOVA, LSD-t, AST, ALB, ALT
Mappa
| Data Statement: Data sharing is not applicable to this article as no new data were created or analyzed in this study. |
|
| Declaration of interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. |
Vol 46 - N° 4
Articolo 101819- Aprile 2022 Ritorno al numero
Articolo precedente
- Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials
- Lei Sun, Chaohua Deng, Yunpeng Gu, Yining He, Luping Yang, Junping Shi
- Acute kidney injury in patients with cirrhosis: Prospective longitudinal study in 405 patients
- Lucile Moga, Marie-Angèle Robic, Hélène Blasco-Perrin, Pauline Cabarrou, Julie Mogno, Maëva Guillaume, Jean Pierre Vinel, Jean-Marie Péron, Christophe Bureau
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?